TY - JOUR
T1 - Telangiectasia and pulmonary arterial hypertension following treatment with trastuzumab emtansine
T2 - A case report
AU - Kwon, Younghoon
AU - Gomberg-Maitland, Mardi
AU - Pritzker, Marc
AU - Thenappan, Thenappan
N1 - Publisher Copyright:
Copyright © 2016 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.
PY - 2016/4
Y1 - 2016/4
N2 - Trastuzumab emtansine (T-DM1) is a Food and Drug Administration-approved novel agent for the treatment of HER-2 positive advanced breast cancer. We report a case of pulmonary arterial hypertension (PAH) that we attribute to the use of T-DM1. A 43-year-old woman with stage IV breast cancer presented with dyspnea on exertion. After excluding other secondary causes of pulmonary hypertension, a diagnosis of moderately severe PAH was made based on right heart catheterization. History revealed that the patient had been on T-DM1 before presentation. During T-DM1 treatment, the patient experienced hereditary hemorrhagic telangiectasia-like symptoms consisting of spider angiomata-skin lesions, epistaxis, and hematochezia, which resolved with discontinuation of T-DM1. Temporal associations of T-DM1 use with the development of PAH in the patient, and the reported association between hereditary hemorrhagic telangiectasia and PAH via genetic linkage, led us to suspect T-DM1 as the cause of PAH.
AB - Trastuzumab emtansine (T-DM1) is a Food and Drug Administration-approved novel agent for the treatment of HER-2 positive advanced breast cancer. We report a case of pulmonary arterial hypertension (PAH) that we attribute to the use of T-DM1. A 43-year-old woman with stage IV breast cancer presented with dyspnea on exertion. After excluding other secondary causes of pulmonary hypertension, a diagnosis of moderately severe PAH was made based on right heart catheterization. History revealed that the patient had been on T-DM1 before presentation. During T-DM1 treatment, the patient experienced hereditary hemorrhagic telangiectasia-like symptoms consisting of spider angiomata-skin lesions, epistaxis, and hematochezia, which resolved with discontinuation of T-DM1. Temporal associations of T-DM1 use with the development of PAH in the patient, and the reported association between hereditary hemorrhagic telangiectasia and PAH via genetic linkage, led us to suspect T-DM1 as the cause of PAH.
KW - Chemotherapy
KW - Oncology
KW - Pulmonary hypertension
UR - http://www.scopus.com/inward/record.url?scp=84964474550&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964474550&partnerID=8YFLogxK
U2 - 10.1016/j.chest.2015.09.008
DO - 10.1016/j.chest.2015.09.008
M3 - Article
C2 - 27055712
AN - SCOPUS:84964474550
SN - 0012-3692
VL - 149
SP - e103-e105
JO - CHEST
JF - CHEST
IS - 4
ER -
